Patents by Inventor Jae Bong Yoon

Jae Bong Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO IL-17A AND TNF-Alpha
    Publication number: 20220098297
    Abstract: A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-?. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-? and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-?, it has an advantage of improving the treatment effect with lower dose.
    Type: Application
    Filed: April 20, 2020
    Publication date: March 31, 2022
    Inventors: Jae Bong YOON, Eun Young JEON, Gi Sun BAEK, Seok Ho YOO, Bum-Chan PARK, Young Woo PARK
  • EGFRvIII antibody and composition comprising same
    Patent number: 10597457
    Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 24, 2020
    Assignee: PHARMABCINE INC.
    Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
  • Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same
    Patent number: 10155817
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: December 18, 2018
    Assignee: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • Human antibody specific to c-Met and preparation method thereof
    Patent number: 10106622
    Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: October 23, 2018
    Assignee: PHARMABCINE INC.
    Inventors: Jinsang Yoo, Ju Ryoung Nam, Jin San Yoo, Sung-Woo Kim, Weon Sup Lee, Sang Ryeol Shim, Sang Soon Byun, Miju Park, Hyuk Joon Lee, Do Yun Kim, Yeon Ju Kim, Mi Ae Jeon, Jinhee Choi, Youngae Lee, Kyoung Hee Nahm, Boyoung Jeong, Seon Young Lee, Jong Geun Jeong, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh, Eun Hee Lee, Ji Hye Jeong
  • DUAL-TARGET ANTIBODY TARGETING VEGFR-2 AND DLL4, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
    Publication number: 20180208660
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Applicant: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same
    Patent number: 9963512
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: May 8, 2018
    Assignee: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
  • NOVEL EGFRVIII ANTIBODY AND COMPOSITION COMPRISING SAME
    Publication number: 20170327585
    Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.
    Type: Application
    Filed: November 25, 2014
    Publication date: November 16, 2017
    Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
  • HUMAN ANTIBODY SPECIFIC TO C-MET AND PREPARATION METHOD THEREOF
    Publication number: 20170233492
    Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.
    Type: Application
    Filed: July 28, 2015
    Publication date: August 17, 2017
    Inventors: Jinsang Yoo, Ju Ryoung Nam, Jin San Yoo, Sung-Woo Kim, Weon Sup Lee, Sang Ryeol Shim, Sang Soon Byun, Miju Park, Hyuk Joon Lee, Do Yun Kim, Yeon Ju Kim, Mi Ae Jeon, Jinhee Choi, Youngae Lee, Kyoung Hee Nahm, Boyoung Jeong, Seon Young Lee, Jong Geun Jeong, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh, Eun Hee Lee, Ji Hye Jeong
  • DUAL-TARGET ANTIBODY TARGETING VEGFR-2 AND DLL4, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
    Publication number: 20150315277
    Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
    Type: Application
    Filed: November 20, 2013
    Publication date: November 5, 2015
    Applicant: PharmAbcine Inc.
    Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh